145 related articles for article (PubMed ID: 33046053)
1. Bone turnover biomarkers in COPD patients randomized to either a regular or shortened course of corticosteroids: a substudy of the randomized controlled CORTICO-COP trial.
Sivapalan P; Jørgensen NR; Mathioudakis AG; Eklöf J; Lapperre T; Ulrik CS; Andreassen HF; Armbruster K; Sivapalan P; Janner J; Godtfredsen N; Weinreich UM; Nielsen TL; Seersholm N; Wilcke T; Schuetz P; Klausen TW; Marså K; Vestbo J; Jensen JU
Respir Res; 2020 Oct; 21(1):263. PubMed ID: 33046053
[TBL] [Abstract][Full Text] [Related]
2. A multi-center randomized, controlled, open-label trial evaluating the effects of eosinophil-guided corticosteroid-sparing therapy in hospitalised patients with COPD exacerbations - The CORTICO steroid reduction in COPD (CORTICO-COP) study protocol.
Sivapalan P; Moberg M; Eklöf J; Janner J; Vestbo J; Laub RR; Browatzki A; Armbruster K; Wilcke JT; Seersholm N; Weinreich UM; Titlestad IL; Andreassen HF; Ulrik CS; Bødtger U; Nielsen TL; Hansen EF; Jensen JUS
BMC Pulm Med; 2017 Aug; 17(1):114. PubMed ID: 28810909
[TBL] [Abstract][Full Text] [Related]
3. Eosinophil-guided corticosteroid therapy in patients admitted to hospital with COPD exacerbation (CORTICO-COP): a multicentre, randomised, controlled, open-label, non-inferiority trial.
Sivapalan P; Lapperre TS; Janner J; Laub RR; Moberg M; Bech CS; Eklöf J; Holm FS; Armbruster K; Sivapalan P; Mosbech C; Ali AKM; Seersholm N; Wilcke JT; Brøndum E; Sonne TP; Rønholt F; Andreassen HF; Ulrik CS; Vestbo J; Jensen JS
Lancet Respir Med; 2019 Aug; 7(8):699-709. PubMed ID: 31122894
[TBL] [Abstract][Full Text] [Related]
4. Effect of different corticosteroid regimes for hospitalised patients with exacerbated COPD: pooled analysis of individual participant data from the REDUCE and CORTICO-COP trials.
Sivapalan P; Rutishauser J; Ulrik CS; Leuppi JD; Pedersen L; Mueller B; Eklöf J; Biering-Sørensen T; Gottlieb V; Armbruster K; Janner J; Moberg M; Lapperre TS; Nielsen TL; Browatzki A; Mathioudakis A; Vestbo J; Schüetz P; Jensen JU
Respir Res; 2021 May; 22(1):155. PubMed ID: 34020641
[TBL] [Abstract][Full Text] [Related]
5. Reduction of corticosteroid use in outpatient treatment of exacerbated COPD - Study protocol for a randomized, double-blind, non-inferiority study, (The RECUT-trial).
Urwyler P; Boesing M; Abig K; Cattaneo M; Dieterle T; Zeller A; Bachler H; Markun S; Senn O; Merlo C; Essig S; Ullmer E; Rutishauser J; Schuurmans MM; Leuppi JD
Trials; 2019 Dec; 20(1):727. PubMed ID: 31842993
[TBL] [Abstract][Full Text] [Related]
6. Corticosteroids in the treatment of acute exacerbations of chronic obstructive pulmonary disease.
Woods JA; Wheeler JS; Finch CK; Pinner NA
Int J Chron Obstruct Pulmon Dis; 2014; 9():421-30. PubMed ID: 24833897
[TBL] [Abstract][Full Text] [Related]
7. Low-dose oral theophylline combined with inhaled corticosteroids for people with chronic obstructive pulmonary disease and high risk of exacerbations: a RCT.
Devereux G; Cotton S; Fielding S; McMeekin N; Barnes PJ; Briggs A; Burns G; Chaudhuri R; Chrystyn H; Davies L; Soyza A; Gompertz S; Haughney J; Innes K; Kaniewska J; Lee A; Morice A; Norrie J; Sullivan A; Wilson A; Price D
Health Technol Assess; 2019 Jul; 23(37):1-146. PubMed ID: 31343402
[TBL] [Abstract][Full Text] [Related]
8. Prospective follow-up of novel markers of bone turnover in persistent asthmatics exposed to low and high doses of inhaled ciclesonide over 12 months.
Anderson WJ; McFarlane LC; Lipworth BJ
J Clin Endocrinol Metab; 2012 Jun; 97(6):1929-36. PubMed ID: 22438232
[TBL] [Abstract][Full Text] [Related]
9. Different durations of corticosteroid therapy for exacerbations of chronic obstructive pulmonary disease.
Walters JA; Tan DJ; White CJ; Wood-Baker R
Cochrane Database Syst Rev; 2014 Dec; (12):CD006897. PubMed ID: 25491891
[TBL] [Abstract][Full Text] [Related]
10. Effect of Theophylline as Adjunct to Inhaled Corticosteroids on Exacerbations in Patients With COPD: A Randomized Clinical Trial.
Devereux G; Cotton S; Fielding S; McMeekin N; Barnes PJ; Briggs A; Burns G; Chaudhuri R; Chrystyn H; Davies L; De Soyza A; Gompertz S; Haughney J; Innes K; Kaniewska J; Lee A; Morice A; Norrie J; Sullivan A; Wilson A; Price D
JAMA; 2018 Oct; 320(15):1548-1559. PubMed ID: 30326124
[TBL] [Abstract][Full Text] [Related]
11. Observational Study to Evaluate the Effect of Epidural Steroid Injection on Bone Mineral Density and Bone Turnover Markers.
Jain A; Gupta P; Chaurasia R; Singh M; Pandey S
Pain Physician; 2020 Sep; 23(5):E517-E524. PubMed ID: 32967402
[TBL] [Abstract][Full Text] [Related]
12. Personalized Variable vs Fixed-Dose Systemic Corticosteroid Therapy in Hospitalized Patients With Acute Exacerbations of COPD: A Prospective, Multicenter, Randomized, Open-Label Clinical Trial.
Li L; Zhao N; Ma X; Sun F; He B; Qin Z; Wu K; Wang X; Zhao Q; Zhang S; Nie N; Luo D; Sun B; Shen Y; He Y; Wen F; Zheng J; Jones P; Cao G
Chest; 2021 Nov; 160(5):1660-1669. PubMed ID: 34023318
[TBL] [Abstract][Full Text] [Related]
13. Differential impact of glucose administered intravenously or orally on bone turnover markers in healthy male subjects.
Westberg-Rasmussen S; Starup-Linde J; Hermansen K; Holst JJ; Hartmann B; Vestergaard P; Gregersen S
Bone; 2017 Apr; 97():261-266. PubMed ID: 28126633
[TBL] [Abstract][Full Text] [Related]
14. Inhaled corticosteroids versus long-acting beta(2)-agonists for chronic obstructive pulmonary disease.
Spencer S; Evans DJ; Karner C; Cates CJ
Cochrane Database Syst Rev; 2011 Oct; (10):CD007033. PubMed ID: 21975759
[TBL] [Abstract][Full Text] [Related]
15. Effect of isolated vitamin D supplementation on bone turnover markers in younger postmenopausal women: a randomized, double-blind, placebo-controlled trial.
Nahas-Neto J; Cangussu LM; Orsatti CL; Bueloni-Dias FN; Poloni PF; Schmitt EB; Nahas EAP
Osteoporos Int; 2018 May; 29(5):1125-1133. PubMed ID: 29450585
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness using higher inhaled corticosteroid dosage in patients with COPD by different blood eosinophilic counts.
Cheng SL; Lin CH
Int J Chron Obstruct Pulmon Dis; 2016; 11():2341-2348. PubMed ID: 27703344
[TBL] [Abstract][Full Text] [Related]
17. Blood Eosinophil Counts, Withdrawal of Inhaled Corticosteroids and Risk of COPD Exacerbations and Mortality in the Clinical Practice Research Datalink (CPRD).
Oshagbemi OA; Franssen FME; van Kraaij S; Braeken DCW; Wouters EFM; Maitland-van der Zee AH; Driessen JHM; de Vries F
COPD; 2019 Apr; 16(2):152-159. PubMed ID: 31117850
[TBL] [Abstract][Full Text] [Related]
18. Effects of denosumab on bone turnover markers in postmenopausal osteoporosis.
Eastell R; Christiansen C; Grauer A; Kutilek S; Libanati C; McClung MR; Reid IR; Resch H; Siris E; Uebelhart D; Wang A; Weryha G; Cummings SR
J Bone Miner Res; 2011 Mar; 26(3):530-7. PubMed ID: 20839290
[TBL] [Abstract][Full Text] [Related]
19. Systemic corticosteroid for COPD exacerbations, whether the higher dose is better? A meta-analysis of randomized controlled trials.
Cheng T; Gong Y; Guo Y; Cheng Q; Zhou M; Shi G; Wan H
Clin Respir J; 2013 Oct; 7(4):305-18. PubMed ID: 23072733
[TBL] [Abstract][Full Text] [Related]
20. Extended Versus Short-Course Corticosteroid Taper Regimens in the Management of Chronic Obstructive Pulmonary Disease Exacerbations in Critically Ill Patients.
Poon T; Paris DG; Aitken SL; Patrawalla P; Bondarsky E; Altshuler J
J Intensive Care Med; 2020 Mar; 35(3):257-263. PubMed ID: 29161935
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
